The CS/DCX-PLGA oral formulation, whose extensive in vitro characterization studies have been completed, showed high mucin interaction, high mucus penetration, high anticancer activity in a colon cancer cell line, and high intestinal permeability. Here, MUC5AC is linked to colonic neoplasm.